Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10218896 | 0.85 | MCL1 (0.57) | MCL1SMN1; SMN2MAPTKMT2ANPC1 | |
| SCHEMBL15114753 | 0.84 | KDM4E (0.50) | HTR2ASLC6A4KCNH2SMN1; SMN2LMNA | |
| SCHEMBL26349351 | 0.83 | DRD2 (0.55) | DRD2DRD4DRD3HPGDMCL1 | |
| SCHEMBL10271335 | 0.82 | HPGD (0.49) | DRD2DRD4DRD3HPGDSMN1; SMN2 | |
| SCHEMBL17658992 | 0.81 | MRGPRX4 (0.40) | HPGDSLC6A4CYP3A4SMN1; SMN2MAPT | |
| SCHEMBL6301020 | 0.80 | NQO1 (0.52) | DRD2DRD4DRD3HPGDMCL1 | |
| SCHEMBL1958623 | 0.79 | TSHR (0.42) | MCL1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL19816715 | 0.79 | MAPT (0.44) | HTR2ASLC6A4KCNH2SMN1; SMN2MAPT | |
| SCHEMBL27172043 | 0.79 | KDM4E (0.36) | HPGDMCL1SLC6A4KCNH2SMN1; SMN2 | |
| SCHEMBL30922427 | 0.79 | CYP3A4 (0.42) | DRD4HPGDCYP3A4SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184462-A1 | METHOD FOR PREDICTING AND MODELING ANTI-PSYCHOTIC ACTIVITY USING VIRTUAL SCREENING MODEL | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-18 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | DRD2 4099/4885DRD4 3920/4885DRD3 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.